Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BENNETT MYERS

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1437211414
CMS profile
65396
Location
AMHERST, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$30,435.00

263 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Page 3 of 6; records 101–150 of 263 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BENNETT MYERS

NPI 1437211414 · CMS profile ID 65396

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

AMHERST, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 6; records 101–150 of 263 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1437211414?year=2021&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BENNETT MYERS, NPI 1437211414, CMS profile ID 65396. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 6; records 101–150 of 263 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1437211414?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). BENNETT MYERS, NPI 1437211414, CMS profile ID 65396. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 6; records 101–150 of 263 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1437211414?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
BENNETT MYERS, NPI 1437211414, CMS profile ID 65396, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 6; records 101–150 of 263 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1437211414?year=2021&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

263 matching records · $30,435.00 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 263 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 263.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Celgene Corporation $17.9107/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783698671 CMS
Janssen Pharmaceuticals, Inc $16.6207/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788233925 CMS
Sobi, Inc $17.8907/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851497593 CMS
Genentech USA, Inc. $12.3207/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835892249 CMS
Merz Pharmaceuticals, LLC $17.3607/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845431675 CMS
Adamas Pharmaceuticals, Inc. $23.9107/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834402165 CMS
GE HEALTHCARE $8.3207/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 837881263 CMS
GE HEALTHCARE $8.3207/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 837886905 CMS
Janssen Pharmaceuticals, Inc $12.5407/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788233923 CMS
Novartis Pharmaceuticals Corporation $8.6807/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813106219 CMS
Alnylam Pharmaceuticals Inc. $17.7507/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 828515163 CMS
Genentech USA, Inc. $13.4107/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835892247 CMS
EMD Serono, Inc. $125.0007/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849148079 CMS
Alexion Pharmaceuticals, Inc. $20.2107/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783120955 CMS
Janssen Pharmaceuticals, Inc $11.5807/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788233921 CMS
MITSUBISHI TANABE PHARMA AMERICA, INC. $16.0807/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 844025099 CMS
Biohaven Pharmaceuticals, Inc. $11.1107/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852573673 CMS
ACADIA Pharmaceuticals Inc $0.8306/30/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838012549 CMS
ACADIA Pharmaceuticals Inc $10.0806/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838012553 CMS
Merz Pharmaceuticals, LLC $437.5006/30/2021 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845431681 CMS
Neurocrine Biosciences, Inc. $29.6206/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 837806997 CMS
Teva Pharmaceuticals USA, Inc. $17.2006/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839461825 CMS
Teva Pharmaceuticals USA, Inc. $18.5306/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839461829 CMS
Mallinckrodt Hospital Products Inc. $13.7906/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845371133 CMS
Novartis Pharmaceuticals Corporation $20.7406/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813106215 CMS
Merz Pharmaceuticals, LLC $23.7506/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845431677 CMS
Alexion Pharmaceuticals, Inc. $15.4406/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783120897 CMS
Genentech USA, Inc. $15.5806/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835892243 CMS
GE HEALTHCARE $9.6606/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 837880069 CMS
Janssen Pharmaceuticals, Inc $8.7506/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788233919 CMS
Novartis Pharmaceuticals Corporation $17.6506/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813106227 CMS
Allergan, Inc. $17.3606/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792884213 CMS
GE HEALTHCARE $8.0206/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 837880167 CMS
Ipsen Biopharmaceuticals, Inc $12.9306/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 841907171 CMS
Neurocrine Biosciences, Inc. $8.7506/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 837806995 CMS
GENZYME CORPORATION $11.5406/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843526639 CMS
Genentech USA, Inc. $13.3206/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835892241 CMS
BANNER LIFE SCIENCES, LLC $12.5906/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843738221 CMS
PFIZER INC. $12.8306/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832506416 CMS
Alexion Pharmaceuticals, Inc. $19.5606/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783120895 CMS
Biogen, Inc. $17.6506/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827827401 CMS
Novartis Pharmaceuticals Corporation $8.7606/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813106211 CMS
Teva Pharmaceuticals USA, Inc. $12.5806/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839461821 CMS
Genentech, Inc. $1,910.0006/04/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835892297 CMS
Horizon Therapeutics plc $11.1906/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797177495 CMS
Amgen Inc. $16.2306/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825178481 CMS
Teva Pharmaceuticals USA, Inc. $20.9506/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839461815 CMS
EMD Serono, Inc. $13.7906/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849191315 CMS
Celgene Corporation $12.1705/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783698665 CMS
Genentech USA, Inc. $19.6905/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835892239 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $71,171.41 363
PY2020 $36,337.19 213
PY2021 $30,435.00 263
PY2022 $74,991.63 318
PY2023 $63,018.46 270
PY2024 $88,225.91 276
PY2025 $67,518.79 271

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $606,546.42 68
PY2024 Principal investigator $348,757.86 71
PY2023 Principal investigator $474,816.66 60
PY2022 Principal investigator $242,272.66 27
PY2021 Principal investigator $269,575.74 29
PY2020 Principal investigator $683,169.35 21
PY2019 Principal investigator $405,315.40 12

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

68 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Genentech, Inc. $3,334.62 12/03/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH CENTER INC
Serum Neurofilament Light No dispute reported 06/30/2026 1211596195
Principal investigator 1 Genentech, Inc. $38,867.00 12/03/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH CENTER INC
Phase II dose finding study in prodromal early manifest HD individuals No dispute reported 06/30/2026 1211596370
Principal investigator 1 Genentech, Inc. $7,488.00 12/02/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH CENTER INC
Phase II dose finding study in prodromal early manifest HD individuals No dispute reported 06/30/2026 1211596374
Principal investigator 1 Genentech, Inc. $18,038.10 10/28/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH CENTER INC
Serum Neurofilament Light No dispute reported 06/30/2026 1211596192
Principal investigator 1 Genentech, Inc. $27,224.00 10/28/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH CENTER INC
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211596332
Principal investigator 1 Genentech, Inc. $4,418.00 10/28/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH CENTER INC
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211596336
Principal investigator 1 GENZYME CORPORATION $1,198.00 09/29/2025 Non-covered Recipient Entity
Dent Neurosciences Research Center Inc
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226139094
Principal investigator 1 Roche Products Limited $263.00 09/24/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211596272
Principal investigator 1 Roche Products Limited $263.00 09/24/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211596277
Principal investigator 1 Roche Products Limited $263.00 09/24/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211596281
Principal investigator 1 Roche Products Limited $157.80 09/24/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211596286
Principal investigator 1 Genentech, Inc. $17,810.60 09/11/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH CENTER INC
Serum Neurofilament Light No dispute reported 06/30/2026 1211596187
Principal investigator 1 EMD Serono, Inc. $674.00 09/03/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH CENTER INC
Observational evaluation of Effectiveness And Patient-Reported outcomes (PROs) in suboptimally controlled patients previously taking oral or infusion disease-modifying drugs (DMDs) for relapsing forms of multiple sclerosis (RMS) No dispute reported 06/30/2026 1240118243
Principal investigator 1 EMD Serono, Inc. $674.00 09/03/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH CENTER INC
Observational evaluation of Effectiveness And Patient-Reported outcomes (PROs) in suboptimally controlled patients previously taking oral or infusion disease-modifying drugs (DMDs) for relapsing forms of multiple sclerosis (RMS) No dispute reported 06/30/2026 1240118247
Principal investigator 1 EMD Serono, Inc. $412.00 09/03/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH CENTER INC
Observational evaluation of Effectiveness And Patient-Reported outcomes (PROs) in suboptimally controlled patients previously taking oral or infusion disease-modifying drugs (DMDs) for relapsing forms of multiple sclerosis (RMS) No dispute reported 06/30/2026 1240118254
Principal investigator 1 GENZYME CORPORATION $1,125.00 09/03/2025 Non-covered Recipient Entity
Dent Neurosciences Research Center Inc
A prospective, multicenter, observational, post-authorization safety study (PASS) to evaluate the long term safety profile of LEMTRADA (alemtuzumab) treatment in patients with relapsing forms of multiple sclerosis (RMS) No dispute reported 06/30/2026 1226139090
Principal investigator 1 Genentech, Inc. $582.00 08/26/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH CENTER INC
Ocrelizumab RMS High Dose Study No dispute reported 06/30/2026 1211596328
Principal investigator 1 GENZYME CORPORATION $18,275.80 08/11/2025 Non-covered Recipient Entity
Dent Neurosciences Research Center Inc
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226139072
Principal investigator 1 EMD Serono, Inc. $1,000.00 08/01/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH CENTER INC
Observational evaluation of Effectiveness And Patient-Reported outcomes (PROs) in suboptimally controlled patients previously taking oral or infusion disease-modifying drugs (DMDs) for relapsing forms of multiple sclerosis (RMS) No dispute reported 06/30/2026 1240118250
Principal investigator 1 EMD Serono, Inc. $4,904.00 08/01/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH CENTER INC
Observational evaluation of Effectiveness And Patient-Reported outcomes (PROs) in suboptimally controlled patients previously taking oral or infusion disease-modifying drugs (DMDs) for relapsing forms of multiple sclerosis (RMS) No dispute reported 06/30/2026 1240118258
Principal investigator 1 EMD Serono, Inc. $1,200.00 08/01/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH CENTER INC
Observational evaluation of Effectiveness And Patient-Reported outcomes (PROs) in suboptimally controlled patients previously taking oral or infusion disease-modifying drugs (DMDs) for relapsing forms of multiple sclerosis (RMS) No dispute reported 06/30/2026 1240118262
Principal investigator 1 Genentech, Inc. $22,471.28 07/25/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH CENTER INC
Serum Neurofilament Light No dispute reported 06/30/2026 1211596179
Principal investigator 1 Genentech, Inc. $30,965.00 07/24/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH CENTER INC
Phase II dose finding study in prodromal early manifest HD individuals No dispute reported 06/30/2026 1211596367
Principal investigator 1 Genentech, Inc. $40,685.00 07/21/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH CENTER INC
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211596323
Principal investigator 1 SANOFI US SERVICES INC. $3,985.10 07/14/2025 Non-covered Recipient Entity
Dent Neurosciences Research Center Inc
PHASE 3 Study in Standard of Care Treated Patients with CIDP (Placebo & IVIG comparator) No dispute reported 06/30/2026 1226139028
Principal investigator 1 Genentech, Inc. $236.00 07/01/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH CENTER INC
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211596290
Principal investigator 1 Genentech, Inc. $3,731.00 06/25/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH CENTER INC
Phase II dose finding study in prodromal early manifest HD individuals No dispute reported 06/30/2026 1211596348
Principal investigator 1 Roche Products Limited $263.00 06/25/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211596241
Principal investigator 1 Roche Products Limited $263.00 06/25/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211596244
Principal investigator 1 Roche Products Limited $263.00 06/25/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211596249
Principal investigator 1 Roche Products Limited $263.00 06/25/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211596253
Principal investigator 1 Roche Products Limited $263.00 06/25/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211596257
Principal investigator 1 Roche Products Limited $263.00 06/25/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211596261
Principal investigator 1 Roche Products Limited $263.00 06/25/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211596265
Principal investigator 1 Roche Products Limited $263.00 06/25/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211596268
Principal investigator 1 Genentech, Inc. $12,870.30 06/10/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH CENTER INC
Serum Neurofilament Light No dispute reported 06/30/2026 1211596175
Principal investigator 1 Genentech, Inc. $19,645.00 06/02/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH CENTER INC
Phase II dose finding study in prodromal early manifest HD individuals No dispute reported 06/30/2026 1211596351
Principal investigator 1 Genentech, Inc. $16,247.00 05/09/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH CENTER INC
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211596314
Principal investigator 1 Genentech, Inc. $24,427.72 05/02/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH CENTER INC
Serum Neurofilament Light No dispute reported 06/30/2026 1211596183
Principal investigator 1 Genentech, Inc. $56,025.00 04/29/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH CENTER INC
Phase II dose finding study in prodromal early manifest HD individuals No dispute reported 06/30/2026 1211596363
Principal investigator 1 Genentech, Inc. $125.00 04/16/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH CENTER INC
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211596306
Principal investigator 1 Genentech, Inc. $100.00 04/16/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH CENTER INC
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211596310
Principal investigator 1 Genentech, Inc. $1,104.19 04/08/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH CENTER INC
Ocrelizumab RMS High Dose Study No dispute reported 06/30/2026 1211596319
Principal investigator 1 Roche Products Limited $263.00 03/24/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211596204
Principal investigator 1 Roche Products Limited $263.00 03/24/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211596208
Principal investigator 1 Roche Products Limited $263.00 03/24/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211596212
Principal investigator 1 Roche Products Limited $263.00 03/24/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211596224
Principal investigator 1 Roche Products Limited $263.00 03/24/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211596232
Principal investigator 1 Roche Products Limited $263.00 03/24/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211596236
Principal investigator 1 Genentech, Inc. $26,221.87 02/26/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH CENTER INC
Serum Neurofilament Light No dispute reported 06/30/2026 1211596165
Principal investigator 1 Genentech, Inc. $261.00 02/18/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH CENTER INC
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211596294
Principal investigator 1 Genentech, Inc. $40,685.00 02/14/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH CENTER INC
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211596299
Principal investigator 1 GENZYME CORPORATION $14,370.61 02/10/2025 Non-covered Recipient Entity
Dent Neurosciences Research Center Inc
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226138940
Principal investigator 1 SANOFI US SERVICES INC. $10,800.00 01/27/2025 Non-covered Recipient Entity
Dent Neurosciences Research Center Inc
PHASE 3 Study in Standard of Care Treated Patients with CIDP (Placebo & IVIG comparator) No dispute reported 06/30/2026 1226138920
Principal investigator 1 Genentech, Inc. $519.00 01/17/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH CENTER INC
Ocrevus Subcutaneous Study for Safety and Tolerability No dispute reported 06/30/2026 1211596339
Principal investigator 1 Genentech, Inc. $7,793.00 01/17/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH CENTER INC
Ocrevus Subcutaneous Study for Safety and Tolerability No dispute reported 06/30/2026 1211596344
Principal investigator 1 Genentech, Inc. $53,541.00 01/15/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH CENTER INC
Phase II dose finding study in prodromal early manifest HD individuals No dispute reported 06/30/2026 1211596356
Principal investigator 1 GENZYME CORPORATION $8,273.00 01/13/2025 Non-covered Recipient Entity
Dent Neurosciences Research Center Inc
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226138958
Principal investigator 1 GENZYME CORPORATION $3,402.90 01/13/2025 Non-covered Recipient Entity
Dent Neurosciences Research Center Inc
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226138961
Principal investigator 1 GENZYME CORPORATION $7,303.00 01/13/2025 Non-covered Recipient Entity
Dent Neurosciences Research Center Inc
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226138964
Principal investigator 1 GENZYME CORPORATION $2,124.00 01/13/2025 Non-covered Recipient Entity
Dent Neurosciences Research Center Inc
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226138969
Principal investigator 1 Roche Products Limited $263.00 01/09/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211596199
Principal investigator 1 Roche Products Limited $263.00 01/09/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211596216
Principal investigator 1 Roche Products Limited $263.00 01/09/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211596219
Principal investigator 1 Roche Products Limited $263.00 01/09/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211596228
Principal investigator 1 Genentech, Inc. $125.00 01/08/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH CENTER INC
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211596303
Principal investigator 1 Genentech, Inc. $17,355.60 01/06/2025 Non-covered Recipient Entity
DENT NEUROSCIENCES RESEARCH CENTER INC
Serum Neurofilament Light No dispute reported 06/30/2026 1211596170
Principal investigator 1 Novartis Pharmaceuticals Corporation $28,247.93 01/01/2025 Non-covered Recipient Entity
DENT NEUROLOGIC INSTITUTE
A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Remibrutinib in Patients With Generalized Myasthenia Gravis, Followed by an Open-label Extension Phase No dispute reported 06/30/2026 1190310172

Ownership and Investment Interests

One row per program year and measure, newest year first · the amount invested and the value of the interest are never added together

Program yearMeasureAmountRecords
PY2025 Amount invested $123,317.05 1
PY2025 Value of interest $311,232.16 1
PY2024 Amount invested $66,412.26 1
PY2024 Value of interest $187,915.11 1
PY2023 Amount invested $37,782.55 1
PY2023 Value of interest $121,502.85 1
PY2022 Amount invested $41,463.81 1
PY2022 Value of interest $83,720.30 1
PY2021 Amount invested $17,329.62 1
PY2021 Value of interest $42,256.49 1
PY2020 Amount invested $16,292.35 1
PY2020 Value of interest $24,926.86 1
PY2019 Amount invested $8,290.25 1
PY2019 Value of interest $8,634.52 1

Ownership and Investment Interests are a separate CMS dataset, shown here separately and never added to payments.

Ownership and investment interests are reported as the value of an interest held, not as a payment received. They are a different measure from the payment total on this page and are never combined with it.

Ownership and Investment Interests records

Ordering applied by this site (program year, newest first, then company) · record values are shown as CMS published them

7 records · PY2019–2025

Ownership and Investment Interests records (CSV)

Program yearCompanyAmount invested Value of interestTerms of interestInterest held by Dispute statusPublishedRecord ID
PY2025 NEUROLOGY PRACTICE CONSORTIUM GPO, LLC $123,317.05 $311,232.16 Value of interest is a cumulative total calculated by adding year-over-year ownership values per provider. Payments are made to a group practice, not directly to the physician. We calculate ownership percentage/dollar amount invested by determining the percentage of overhead buy down per physician clinic as a result of the practice ownership in the GPO. Physician Covered Recipient No dispute reported 06/30/2026 1246669600
PY2024 NEUROLOGY PRACTICE CONSORTIUM GPO, LLC $66,412.26 $187,915.11 1.) Value of interest is a cumulative total calculated by adding year-over-year ownership values per provider. 2.) Payments are made to a group practice rather than to a specific physician. The group practice owns 50% of the GPO. We calculate ownership percentage/dollar amount invested by determining the percentage of overhead buydown per physician clinic as a result of the practice ownership in the GPO. Physician Covered Recipient No dispute reported 06/30/2026 1088918200
PY2023 NEUROLOGY PRACTICE CONSORTIUM GPO, LLC $37,782.55 $121,502.85 1.) Value of interest is a cumulative total calculated by adding year-over-year ownership values per provider. 2.) Payments are made to a group practice rather than to a specific physician. The group practice owns 50% of the GPO. We calculate ownership percentage/dollar amount invested by determining the percentage of overhead buydown per physician clinic as a result of the practice ownership in the GPO. Physician Covered Recipient No dispute reported 06/30/2026 1056956169
PY2022 NEUROLOGY PRACTICE CONSORTIUM GPO, LLC $41,463.81 $83,720.30 The organization the physician practices at owns 50% of the GPO, therefore 50% of the profit goes to the medical practice. Physician Covered Recipient No dispute reported 06/30/2026 961918419
PY2021 NEUROLOGY PRACTICE CONSORTIUM GPO, LLC $17,329.62 $42,256.49 The organization the physician practices at owns 50% of the GPO, therefore 50% of the profit goes to the medical practice. Physician Covered Recipient No dispute reported 06/30/2026 851040493
PY2020 NEUROLOGY PRACTICE CONSORTIUM GPO, LLC $16,292.35 $24,926.86 Physician is employed at outpatient neurology practice that owns a percentage of the GPO Physician Covered Recipient No dispute reported 06/30/2026 753247151
PY2019 NEUROLOGY PRACTICE CONSORTIUM GPO, LLC $8,290.25 $8,634.52 Physician is employed at outpatient neurology practice that owns a percentage of the GPO Physician Covered Recipient No dispute reported 06/30/2026 708351893